American BioMed Inc. to accelerate OmniCath atherectomy clinical trials.THE WOODLANDS, Texas--(BUSINESS WIRE)--Jan. 21, 1997--American BioMed Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on OTC/BB:ABMI ABMI Autologous Bone Marrow Infusion ), Tuesday announced that it has added four participating Investigational Sites for its OmniCath(r) Peripheral and AV Fistula clinical trials which brings to six the number of sites participating in the clinical trials. The new investigational sites are: Emory University, Atlanta; State University of New York (body) State University of New York - (SUNY) The public university system of New York State, USA, with campuses throughout the state. , Brooklyn, N.Y.; St. Joseph's Hospital St. Joseph's Hospital may refer to: In the United States:
http://hawaii.edu/uhinfo.html. See also Aloha, Aloha Net. and Kaiser Hospital, Honolulu. The company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steven B. Rash, stated: "The six sites we now have participating in our OmniCath(r) clinical trials will enable the company to accelerate our patient enrollment so that we can conclude the clinical trials in June 1997 and file for FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval by the end of 1997. Medical technology analysts have estimated the worldwide market potential for both peripheral and AV Fistula use to be approximately $300-million. International product sales for the OmniCath(r) are expected to be launched with a strategic partner during the second quarter 1997 while U.S. OmniCath(r) sales are anticipated to begin first quarter 1998. At present, there is no known competitor in the AV Fistula market and only one prominent competitor in the peripheral market." The company further announced that 10 patients have been enrolled in its peripheral trials at UCLA. To date, the trials have progressed according to schedule and there have been no adverse effects or complications with any of the patients. American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually. -0- NOTE TO EDITORS: In the Internet/email address noted in this news release, there is an "at" symbol between tewinc and aol.com. This symbol may not appear properly in some systems. CONTACT: Thomas E. Waite & Associates Inc. Phone 407/324-1606, Fax 407/324-0664 Email: tewinc@aol.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion